Japan's Mochida Pharma To Expand Generic, Biosimilar Cancer Business
This article was originally published in PharmAsia News
Mochida Pharmaceutical plans to expand its generics and biosimilars lines with an eye on building a $110.2 million-a-year business over the next three years, a rate double this year's expected earnings.
You may also be interested in...
Increasing savvy around cybersecurity issues is driving regulators and trade groups to update their approach to the area, speakers from the US FDA and the American Medical Association said at this week’s FDA/CMS Summit.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.